Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography–mass spectrometry
Here we present an optimized workflow for global proteome and phosphoproteome analysis of tissues or cell lines that uses isobaric tags (TMT (tandem mass tags)-10) for multiplexed analysis and relative quantification, and provides 3× higher throughput than iTRAQ (isobaric tags for absolute and relat...
Saved in:
Published in: | Nature protocols Vol. 13; no. 7; pp. 1632 - 1661 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
London
Nature Publishing Group UK
01-07-2018
Nature Publishing Group |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Here we present an optimized workflow for global proteome and phosphoproteome analysis of tissues or cell lines that uses isobaric tags (TMT (tandem mass tags)-10) for multiplexed analysis and relative quantification, and provides 3× higher throughput than iTRAQ (isobaric tags for absolute and relative quantification)-4-based methods with high intra- and inter-laboratory reproducibility. The workflow was systematically characterized and benchmarked across three independent laboratories using two distinct breast cancer subtypes from patient-derived xenograft models to enable assessment of proteome and phosphoproteome depth and quantitative reproducibility. Each plex consisted of ten samples, each being 300 μg of peptide derived from <50 mg of wet-weight tissue. Of the 10,000 proteins quantified per sample, we could distinguish 7,700 human proteins derived from tumor cells and 3100 mouse proteins derived from the surrounding stroma and blood. The maximum deviation across replicates and laboratories was <7%, and the inter-laboratory correlation for TMT ratio–based comparison of the two breast cancer subtypes was
r
> 0.88. The maximum deviation for the phosphoproteome coverage was <24% across laboratories, with an average of >37,000 quantified phosphosites per sample and differential quantification correlations of
r
> 0.72. The full procedure, including sample processing and data generation, can be completed within 10 d for ten tissue samples, and 100 samples can be analyzed in ~4 months using a single LC-MS/MS instrument. The high quality, depth, and reproducibility of the data obtained both within and across laboratories should enable new biological insights to be obtained from mass spectrometry-based proteomics analyses of cells and tissues together with proteogenomic data integration.
This protocol describes a workflow for multiplexed deep-scale, quantitative proteome and phosphoproteome analysis of tumor tissue samples. The procedure includes step-by-step instructions for all stages, from sample preparation to data analysis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 USDOE AC05-76RL01830 PNNL-SA-137930 Conceptualized and designed overall study: K.R.C., L.C.T., M.A. Gillette, P.M., and S.A.C. Led experimental and data analysis efforts at the performance sites: P.M., M.A. Gritsenko., S.A.C., K.K., D.R.M., K.R.C., D.J.C., M.A. Gillette, V.A.P., S.N.T., Z.Z., R.D.S., D.W.C., H.Z., and T.L. Developed PDX benchmarking reference material and distributed to all centers: S.R.D. and R.R.T. Tested and optimized aspects of the experimental protocol: D.J.C., F.M., H.K., L.C.T., M.A. Gritsenko, N.D.U., P.M., P.S., R.J.M., R.Z., S.N.T., and T.R.C. Analyzed the results: D.R.M., F.M., K.R.C., K.K., M.A.G., M.S., M.E.M., P.M., T.L., V.A.P., and Y.H. Wrote the manuscript: H.Z., L.C.T., M.A. Gillette, P.M., K.R.C., and S.A.C. Edited and revised aspects of the text: D.J.C., D.W.C., H.Z., K.K., L.C.T., R.D.S., S.N.T., T.L., V.A.P., Z.Z., R.R.T., and S.R.D. Author contributions |
ISSN: | 1754-2189 1750-2799 |
DOI: | 10.1038/s41596-018-0006-9 |